Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-03-16 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
NOTIFICATION OF BOARD MEETING
Board/Management Information Classification · 95% confidence The document is a notice announcing a forthcoming board meeting to consider the publication of the audited annual results and proposed final dividend. It does not contain the actual annual report or financial results, but rather informs about the meeting where these will be discussed. The document length is short (1627 characters), and it explicitly states the meeting date and agenda. This fits the category of a Board/Management Information announcement, as it relates to board activities and decisions. It is not the annual report itself, nor a report publication announcement, but a notice of a board meeting.
2022-03-16 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is a short announcement from CStone Pharmaceuticals regarding the date of a board meeting to consider and approve the annual results for the year ended December 31, 2021. It does not contain any financial data or the actual annual report but merely informs about the upcoming board meeting and the intention to publish the annual results. The document length is only 1455 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement about the report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2022-03-14 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCED THE NMPA APPROVAL OF GAVRETO (PRALSETINIB) FOR THE TREATMENT OF ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER AND RET FUSION-POSITIVE THYROID CAN
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the approval by the National Medical Products Administration (NMPA) of China for an expanded indication of their drug GAVRETO (pralsetinib). It details the drug's new approved uses, clinical trial results, and background information about the drug and company. There are no financial statements, regulatory certifications, or detailed financial data present. The document is an announcement of a regulatory approval and clinical milestone rather than a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance or officer certification, nor is it a report publication announcement. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about drug approval and clinical data, which does not fit into more specific categories.
2022-03-14 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-03-09 English
Monthly Returns
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on changes in authorised/registered share capital, issued shares, share options, and other share-related movements for Yankuang Energy Group Company Limited. It includes confirmations from a director about the authorization and compliance of these share issuances. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). It is a regulatory filing that reports on share capital and share issuance activities for a specific month (February 2022). It is not an annual or interim financial report, nor an earnings release or management discussion. It is not a proxy statement or voting result announcement. The content aligns with a Share Issue/Capital Change announcement, as it details share capital movements, share options exercised, and share awards issued. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is the report itself, not just an announcement of a report.
2022-03-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued share capital, share options, and confirmations related to securities issued by the company CStone Pharmaceuticals. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules, specifically Chapter 19B. The content includes detailed tables of share capital movements, share options, and confirmations by a company director. There is no indication of financial statements, earnings data, or management discussion. The document is regulatory in nature, reporting share capital and share option movements as required by the exchange rules. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance report submitted to the exchange and does not constitute a financial report, earnings release, or capital change announcement per se. The document length (8916 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2022-03-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.